Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-03-26

FDA Approved: NAGLAZYME — Supplemental Application (BioMarin Pharmaceutical Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Naglazyme (galsulfase) from BioMarin Pharmaceutical Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NAGLAZYME (GALSULFASE)

Snippet

SUPPL AP for NAGLAZYME (GALSULFASE)